Is it worth treating category I failure patients with category II regimen?

Santha, T and Gopi, P G and Rajeswari, R and Selvakumar, N and Subramani, R and Chandrasekaran, V and Rani, B and Thomas, A and Narayanan, P R (2005) Is it worth treating category I failure patients with category II regimen? Indian Journal of Tuberculosis, 52 (4). pp. 203-206. ISSN 0019-5705

Preview

PDF 200538.pdf - Published Version Download (25kB)

Abstract

Background: Very little information is available on the drug susceptibility profile among patients who are treated with standardized short-course chemotherapy regimens under programme conditions. Methods: Sputum samples were collected from new sputum smear-positive patients declared ‘failure’ after treatment with Category I regimen under tuberculosis control programme using DOTS strategy from a rural area of Tamil Nadu. Results: Of 1463 patients started on Category I regimen between May1999 and December 2002, 74 cases were declared as ‘failures’ (smear positive at 5/6 months of treatment). We collected sputum samples from 60 (81%) of 74 ‘failures’ and 27% (16 of 60) of them were culture-negative for M tuberculosis and 17% (10 of 60) had organisms resistant to Isoniazid and Rifampicin (MDR TB). Conclusion: Based on the drug susceptibility profile at the time of ‘failure’, treating Category I ‘failures’ with Category II regimen with close monitoring appears to be justified.

Item Type:	Article
Uncontrolled Keywords:	Tuberculosis, DOTS
Subjects:	Tuberculosis > Clinical Research
Divisions:	Clinical Research
Depositing User:	Dr. Rathinasabapati R
Date Deposited:	28 Nov 2013 10:05
Last Modified:	09 Mar 2016 08:49
URI:	http://eprints.nirt.res.in/id/eprint/716

Actions (login required)

View Item